Clinical Trial

A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Dimensions: NCT03467958

Investigators

Affiliations

Organisations

  1. (1) Bristol-Myers Squibb (United States), grid.419971.3

Sponsors/collaborators

Abstract

This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.

Methods

Condition: Crohn Disease

Intervention: Ozanimod

Recruitment information

Gender: All

Trial period

2018-2026

Phase

Phase 3

External sources

Access at Registry